<DOC>
	<DOCNO>NCT02029287</DOCNO>
	<brief_summary>The purpose study determine whether Hospital-Community-Family-Care Management Platform Chronic Heart Failure reduce mortality , readmission rate cost subject CHF .</brief_summary>
	<brief_title>Hospital-Community-Family-Care Management Platform Chronic Heart Failure</brief_title>
	<detailed_description>( 1 ) Indication : Chronic Heart Failure . ( 2 ) Objectives : Primary objective evaluate efficacy Hospital-Community-Family-Care Management Platform online compare regular clinic follow subject CHF ( II-III class NYHA ) .Secondary objective assess safety Management Platform online subject CHF . ( 3 ) Study design : Prospective , randomize , control study two follow management group : 1 ) Hospital-Community-Family-Care Management Follow Online ; 2 ) regular monthly clinic follow up.Study population : Totally 1000 male female subject CHF ( II-III functional class accord NYHA classification ) . ( 4 ) Quality assurance plan address data validation registry procedure , include plan site monitoring audit . ( 5 ) Data check compare data enter registry predefined rule range consistency data field registry . ( 6 ) Source data verification ass accuracy , completeness , representativeness registry data compare data external data source . ( 7 ) Standard Operating Procedures address registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management . ( 8 ) Duration follow : The total follow-up time shall 12 month . ( 9 ) Safety Assessment : Safety study evaluate follow assessment : 1 ) Subject examination ( follow period extend 2 week end study ) consist subject interview ( include direct question adverse event ) , physical examination , assessment body weight , Electrocardiogram ( ECG ) echocardiogram ( UCG ) , Left ventricular ejection fraction , assess echocardiography , The N-terminal prohormone brain natriuretic peptide ( NT-proBNP ) , peptide hormone whose plasma concentration inversely related severity HF , NYHA functional status , assess subject interview , Quality life ( QoL ) , assess Minnesota Living Heart Failure questionnaire ( MLHFQ ) , validate questionnaire assess QoL subject heart failure . 2 ) Evaluation clinically relevant safety laboratory parameter , complete blood count , serum creatinine , electrolytes , liver enzymes.Any Adverse Events ( AE ) Serious Adverse Events ( SAE ) potential causal relationship study record evaluate . ( 10 )</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>consider eligible participate study , subject must meet inclusion criterion list time screen randomization : 1 . Male female subject≥18 year age . 2 . History CHF ≥3 month NYHA functional class IIIII . 3 . Left ventricular ejection fraction ≤45 % assessed echocardiogram . 4 . Treatment CHF stable optimal pharmacological therapy accord Chinese guideline treatment CHF . In general , optimal treatment include betablocker ACE inhibitor and/or angiotensin receptor blocker , unless tolerate . Medical therapy define stable , subject start new CHF drug class dose drug take change 3 month prior screen randomization . 5 . Ability understand requirement study willingness provide write informed consent ( IC ) , agreement abide study restriction return required assessment . 6 . Subjects locate coverage remote monitoring system . To eligible entry study , subject must meet exclusion criterion list screen randomization : 1 . Abnormal renal hepatic function , define ALT≥100 u/L , serum creatinine &gt; 3.0mg/dL , serum albumin ＜2.5g/L . 2 . Hemoglobin concentration≤8.0g/dL . 3 . Obesity ( body mass index &gt; 35kg/m2 ) . 4 . Heart failure primarily due valvular heart disease , clinically significant valvular heart disease expect require surgical correction within 12 month randomization . 5 . Implantable cardiac defibrillator ( ICD ) within 30 day prior randomization , initiation cardiac resynchronization therapy ( CRT with/without ICD ) within 30 day prior randomization . 6 . Routinely schedule IV infusion HF ( e.g. , inotropes , vasodilator , diuretic ) . 7 . Acute myocardial infarction cerebrovascular accident within 6 month prior randomization . 8 . Percutaneous intervention ( coronary , cerebrovascular , aortic ) within 6 month prior randomization . 9 . Major surgery , include thoracic cardiac surgery , within 3 month prior randomization . 10 . Symptomatic tachyarrhythmia uncontrolled ventricular response ( &gt; 100 bpm rest ) untreated symptomatic bradyarrhythmia within 1 month prior randomization . 11 . Hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis . 12 . Likelihood cardiac transplantation within 12 month randomization . 13 . Peripheral artery disease , interfere 6 minute walk test . 14 . Chronic obstructive pulmonary disease , interfere 6 minute walk test . 15 . History major organ transplant ( e.g. , lung , liver , heart , bone marrow ) renal replacement therapy . 16 . Serious anaemia secondary acute chronic bleeding . 17 . Whole blood red blood cell ( RBC ) transfusion within 8 week prior randomization . 18 . Severe concomitant noncardiovascular disease expect reduce life expectancy le 3 year . 19 . History neoplastic disease . 20 . Known active systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia ) , hemolysis due cause , thalassemia . 21 . Untreated hypo hyperthyroidism , adrenal insufficiency , active vasculitis due collagen vascular disease . 22 . Use erythropoietic protein ( eg , rHuEPO ) within 12 week prior randomization . 23 . Pregnancy ( e.g . positive human chorionic gonadotropin [ HCG ] test ) active lactation . 24 . Currently recently ( &lt; 30 day ) enrol clinical trial investigational device , currently receive investigational agent ( ) procedure ( ) . 25 . Disorder compromise ability subject give write informed consent comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic heart failure</keyword>
	<keyword>telemedicine</keyword>
	<keyword>health service platform</keyword>
</DOC>